US 12,018,025 B2
Integrin inhibitor and uses thereof
Jacob Cha, San Bruno, CA (US); Katerina Leftheris, San Mateo, CA (US); Qi Gao, Franklin Park, NJ (US); Jian Wang, Branchburg, NJ (US); and Dalian Zhao, Fanwood, NJ (US)
Assigned to PLIANT THERAPEUTICS, INC., South San Francisco, CA (US)
Filed by Pliant Therapeutics, Inc., South San Francisco, CA (US)
Filed on Nov. 19, 2021, as Appl. No. 17/531,074.
Claims priority of provisional application 63/116,042, filed on Nov. 19, 2020.
Prior Publication US 2022/0177468 A1, Jun. 9, 2022
Int. Cl. C07D 471/04 (2006.01)
CPC C07D 471/04 (2013.01) [C07B 2200/13 (2013.01)] 163 Claims
 
1. A crystalline form of a phosphate salt of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(quinazolin-4-ylamino)butanoic acid, wherein the crystalline form is characterized as having an X-ray powder diffraction (XRPD) pattern comprising:
a. peaks at angles 2-theta of about 4.31, about 6.76, about 18.89, about 21.29, and about 23.16 degrees,
b. peaks at angles 2-theta of about 4.31, about 6.76, about 11.25, about 12.75, about 18.89, about 20.38, about 21.29, about 23.16, about 23.97, and about 24.68 degrees, or
c. peaks at angles 2-theta of about 4.31, about 6.76, about 8.55, about 10.04, about 11.25, about 12.75, about 13.76, about 17.20, about 18.02, about 18.89, about 20.38, about 21.29, about 23.16, about 23.97, about 24.68, about 25.50, about 26.18, about 29.88, and about 33.49 degrees.